The Effects on Metabolic Syndrome Parameters of Atypical Antipsychotic Agents in Schizophrenics Patients : 3 Years Retrospective Follow Up.
10.16946/kjsr.2017.20.1.5
- Author:
Ha Hyun BAE
1
;
Hai Joo YOON
;
Eun Kyung PARK
;
Jong Il LEE
Author Information
1. Department of Psychiatry, National Center for Mental Health, Seoul, Korea. lji7542@naver.com
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Atypical antipsychotics;
Metabolic syndrome
- MeSH:
Antipsychotic Agents*;
Aripiprazole;
Blood Glucose;
Blood Pressure;
Cholesterol;
Cholesterol, HDL;
Follow-Up Studies*;
Hematologic Tests;
Hospitals, Psychiatric;
Humans;
Mass Screening;
Medical Records;
Obesity, Abdominal;
Paliperidone Palmitate;
Prevalence;
Retrospective Studies*;
Schizophrenia;
Secondary Prevention;
Triglycerides;
Waist Circumference;
Weight Gain
- From:Korean Journal of Schizophrenia Research
2017;20(1):5-14
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Pharmacological treatment is critical on relapse prevention in patients with schizophrenia. However, atypical antipsychotic agents are known to cause weight gain more than typical agents despite their various effects. In addition, they are known to affect blood sugar, blood pressure, cholesterol, cardiac function, and sexual function. This study was designed to examine the effects on metabolic parameters when schizophrenic patients have been taken atypical antipsychotic agents. METHODS: This was a trial in 137 patients with DSM-IV-TR schizophrenia who were admitted or treated in mental hospital. Anthropometric measurement and blood testing were conducted at baseline, 12 month, 36 month, and sociodemographic and treatment history were collected from medical records. We conducted height, weight, waist circumference, blood pressure, FBS, total cholesterol, HDL, triglyceride, and QTc interval. Metabolic syndrome was diagnosed by ATPIIIa criteria. RESULTS: Aripiprazole showed the significant difference in the impact on weight, blood pressure, waist circumference, total cholesterol, HDL, triglyceride than paliperidone and olanzapine at 1-year and 3-year period. Olanzapine showed the significant increase of weight and triglyceride than paliperidone at 3-year period. The prevalence of metabolic syndrome increased in paliperidone at 1-year and in olanzapine at 3-year period compared to aripiprazole significantly. CONCLUSION: We concluded that aripiprazole has less impact on the abdominal obesity, FBS, blood pressure, and cholesterol than paliperidone and olanzapine. Olanzapine showed the increase of long-term metabolic risk than other agents. There was needed the routine screening and multidisciplinary management of medical problems in schizophrenic patients for the prevention of metabolic syndrome.
